Pancreatic Hormones

Pancreatic Hormones
Accession Number

Peptide hormones secreted into the blood by cells in the ISLETS OF LANGERHANS of the pancreas. The alpha cells secrete glucagon; the beta cells secrete insulin; the delta cells secrete somatostatin; and the PP cells secrete pancreatic polypeptide.

ATC Classification
DrugDrug Description
GlucagonA form of recombinant glucagon used to treat hypoglycemia in diabetes mellitus and as a part of gastrointestinal imaging procedures.
Insulin humanA recombinant form of human insulin used to control hyperglycemia in diabetes mellitus.
Insulin detemirA long-acting form of insulin used for glycemic control in type 1 and type 2 diabetes mellitus.
Insulin glulisineA short-acting form of insulin used for glycemic control in type 1 and type 2 diabetes mellitus.
LiraglutideA GLP-1 analog used in the management of type 2 diabetes mellitus and prevention of cardiovascular complications associated with diabetes.
LanreotideA somatostatin analog used for the treatment of unresectable, well- or moderately-differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors and acromegaly.
DulaglutideA GLP-1 agonist used to manage type 2 diabetes mellitus.
SomatostatinA natural peptide hormone used to treat acute bleeding from esophageal varices, gastrointestinal ulcers, and gastritis; prevent pancreatic complications after surgery; and restrict secretions of the upper intestine, pancreas, and biliary tract.
Insulin degludecA long acting insulin used to treat hyperglycemia caused by type 1 and 2 diabetes mellitus.
SemaglutideA glucagon-like peptide 1 receptor agonist used to improve glycemic control in type 2 diabetes mellitus.
Pancreatic PolypeptidePancreatic Polypeptide has been investigated for the treatment of Diabetes Mellitus, Type 1.
AmlintideA medication used in combination with corticosteroids for the treatment of hemorrhoids.
Insulin lisproA modified form of fast-acting insulin used to control hyperglycemia in diabetes mellitus.
Insulin glargineA modified form of long-acting or basal insulin used to control hyperglycemia in diabetes mellitus.
Insulin porkA purified form of porcine insulin used to control hyperglycemia in diabetes mellitus.
PramlintideAn amylin analog used for the management of type 1 and type 2 diabetes mellitus as an adjunct to preprandial insulin therapy in patients without adequate glycemic control of insulin therapy.
Insulin aspartA rapid-acting form of insulin used for glycemic control in type 1 and type 2 diabetes mellitus.
VapreotideFor the treatment of esophageal variceal bleeding in patients with cirrhotic liver disease and has also shown efficacy in the treatment of patients with AIDS-related diarrhea.
NN344Investigated for use/treatment in diabetes mellitus type 1 and 2.
NBI-6024Investigated for use/treatment in diabetes mellitus type 1 and pediatric indications.
PasireotideA somatostatin analog used in the treatment of Cushing’s disease, specifically for those patients whom pituitary surgery is not appropriate.
Insulin peglisproNot Annotated
Indium In-111 pentetreotideIndium In 111 pentetreotide (Octreoscan) has been used in trials studying the diagnostic of SARCOIDOSIS, Solid Tumors, and cushing syndrome.
TT-232Tln 232 is under investigation in clinical trial NCT00422786 (Phase II Study of CAP-232 in Patients With Refractory Metastatic Renal Cell Carcinoma).
PentetreotideA somatostatin receptor inhibitor, available in a kit with Indium-111, used as a contrast agent in the visualization of somatostatin receptor-positive neuroendocrine tumours.
SomatoprimSomatoprim is under investigation for the treatment of Acromegaly.
DasiglucagonA glucagon analog used to treat severe hypoglycemia in pediatric and adult patients with diabetes.
DopastatinDopastatin is under investigation in clinical trial NCT04335357 (TBR-760 in Adult Patients With Non-functioning Pituitary Adenomas).
C-peptideC-peptide is under investigation in clinical trial NCT00278980 (Effect of C-peptide on Diabetic Peripheral Neuropathy).
Pegylated synthetic human c-peptideNot Annotated
Insulin icodecNot Annotated
Drugs & Drug Targets
GlucagonGlucagon receptortarget
GlucagonGlucagon-like peptide 2 receptortarget
GlucagonGlucagon-like peptide 1 receptortarget
Insulin humanInsulin receptortarget
Insulin humanInsulin-like growth factor 1 receptortarget
Insulin humanInsulin-degrading enzymeenzyme
Insulin humanNeuroendocrine convertase 2enzyme
Insulin humanNeuroendocrine convertase 1enzyme
Insulin humanCytochrome P450 1A2enzyme
Insulin humanCarboxypeptidase Etarget
Insulin humanProtein NOV homologtarget
Insulin humanLow-density lipoprotein receptor-related protein 2target
Insulin humanInsulin-like growth factor-binding protein 7target
Insulin detemirInsulin receptortarget
Insulin detemirSerum albumincarrier
Insulin detemirInsulin-like growth factor 1 receptortarget
Insulin detemirCytochrome P450 1A2enzyme
Insulin glulisineInsulin receptortarget
Insulin glulisineInsulin-like growth factor 1 receptortarget
Insulin glulisineCytochrome P450 1A2enzyme
LiraglutideGlucagon-like peptide 1 receptortarget
LiraglutideDipeptidyl peptidase 4enzyme
LiraglutideSerum albumincarrier
LanreotideSomatostatin receptor type 2target
LanreotideSomatostatin receptor type 5target
LanreotideCytochrome P450 3A4enzyme
DulaglutideGlucagon-like peptide 1 receptortarget
SomatostatinSomatostatin receptor type 1target
SomatostatinSomatostatin receptor type 2target
SomatostatinSomatostatin receptor type 3target
SomatostatinSomatostatin receptor type 4target
SomatostatinSomatostatin receptor type 5target
SomatostatinP-glycoprotein 1transporter
SomatostatinCytochrome P450 3A4enzyme
Insulin degludecInsulin receptortarget
Insulin degludecInsulin-like growth factor 1 receptortarget
Insulin degludecSerum albumincarrier
Insulin degludecCytochrome P450 1A2enzyme
SemaglutideSerum albumincarrier
SemaglutideDipeptidyl peptidase 4enzyme
SemaglutideGlucagon-like peptide 1 receptortarget
SemaglutideLipoprotein lipaseenzyme
SemaglutideAlpha-amylase 1enzyme
Insulin lisproInsulin receptortarget
Insulin lisproInsulin-like growth factor 1 receptortarget
Insulin lisproCytochrome P450 1A2enzyme
Insulin lisproInsulin-degrading enzymeenzyme
Insulin glargineInsulin receptortarget
Insulin glargineInsulin-like growth factor 1 receptortarget
Insulin glargineCytochrome P450 1A2enzyme
Insulin porkInsulin receptortarget
Insulin porkInsulin-like growth factor 1 receptortarget
Insulin porkCytochrome P450 1A2enzyme
Insulin porkInsulin-degrading enzymeenzyme
PramlintideReceptor activity-modifying protein 1target
PramlintideReceptor activity-modifying protein 2target
PramlintideReceptor activity-modifying protein 3target
PramlintideCalcitonin receptortarget
Insulin aspartInsulin receptortarget
Insulin aspartInsulin-like growth factor 1 receptortarget
Insulin aspartCytochrome P450 1A2enzyme
VapreotideNeurokinin 1 receptortarget
VapreotideSomatostatin receptor type 2target
VapreotideSomatostatin receptor type 5target
VapreotideCytochrome P450 3A4enzyme
NN344Insulin receptortarget
NN344Cytochrome P450 1A2enzyme
PasireotideSomatostatin receptor type 1target
PasireotideSomatostatin receptor type 2target
PasireotideSomatostatin receptor type 3target
PasireotideSomatostatin receptor type 5target
PasireotideCytochrome P450 3A4enzyme
Insulin peglisproCytochrome P450 1A2enzyme
Insulin peglisproInsulin receptortarget
Insulin peglisproInsulin-like growth factor 1 receptortarget
DasiglucagonGlucagon receptortarget